Format

Send to

Choose Destination
See comment in PubMed Commons below
J Rheumatol Suppl. 2012 Jul;89:103-5. doi: 10.3899/jrheum.120258.

Pharmacoeconomic issues in psoriatic arthritis.

Author information

1
Rheumatology Department of Lucania, San Carlo Hospital, Potenza, Italy. ignazioolivieri@tiscalinet.it

Abstract

Therapies for psoriatic arthritis were inadequate until a short time ago. Nonsteroidal antiinflammatory drugs are helpful in relieving symptoms but do not prevent joint damage. Traditional disease-modifying antirheumatic drugs are used to control symptoms, but there is no evidence that they prevent or significantly slow the progression of structural damage in peripheral joints. The introduction of tumor necrosis factor-α (TNF-α) blocking agents has opened new horizons. These drugs lessen signs and symptoms of inflammation, enhance functional capacity and quality of life, and inhibit structural joint damage. On the other hand, TNF-α blockers are very costly and not easily available to all patients, whether they rely on a national health system or on private insurance. Pharmacoeconomic studies on these drugs so far have shown that they are cost-effective on both the musculoskeletal and skin manifestations of psoriatic disease, offering good value for money.

PMID:
22751607
DOI:
10.3899/jrheum.120258
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center